Correction: Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Erratum: Evaluating the Comparative Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in New-Onset Gastric Cancer and Related Gastric Conditions Among Type 2 Diabetes Patients: A Population-Based Cohort Analysis

  • By

  • Oscar Hou In Chou

  • Vinod Kumar Chauhan

  • Cheuk To Skylar Chung

  • Lei Lu

  • Teddy Tai Loy Lee

  • Zita Man Wai Ng

  • Karin Kai Wing Wang

  • Sharen Lee

  • Haipeng Liu

  • Ronald Ting Kai Pang

  • Apichat Kaewdech

  • Bernard Man Yung Cheung

  • Gary Tse

  • Jiandong Zhou

  • August 31, 2026

Share

Clinical Scorecard: Erratum: Evaluating the Comparative Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in New-Onset Gastric Cancer and Related Gastric Conditions Among Type 2 Diabetes Patients: A Population-Based Cohort Analysis

At a Glance

CategoryDetail
ConditionGastric Cancer
Key MechanismsSodium-Glucose Cotransporter-2 Inhibitors
Target PopulationType 2 Diabetes Patients
Care SettingPopulation-Based Cohort Analysis

Key Highlights

  • Correction of inaccurate affiliation details
  • Revisions made to the original article
  • Focus on comparative efficacy of treatment

Guideline-Based Recommendations

Diagnosis

  • Specific diagnostic criteria for gastric cancer in type 2 diabetes patients.

Management

  • Management strategies for gastric conditions in type 2 diabetes.

Monitoring & Follow-up

  • Monitoring protocols for patients on Sodium-Glucose Cotransporter-2 Inhibitors.

Risks

  • Potential risks associated with Sodium-Glucose Cotransporter-2 Inhibitors in this population.

Patient & Prescribing Data

Type 2 Diabetes Patients with Gastric Conditions

Focus on Sodium-Glucose Cotransporter-2 Inhibitors

Clinical Best Practices

  • Best practices for prescribing Sodium-Glucose Cotransporter-2 Inhibitors in type 2 diabetes patients with gastric conditions.

Related Resources & Content

Original Source(s)

Correction: Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors for new-onset gastric cancer and gastric diseases in patients with type 2 diabetes mellitus: a population-based cohort study

  • by Oscar Hou In Chou, Vinod Kumar Chauhan, Cheuk To Skylar Chung, Lei Lu, Teddy Tai Loy Lee, Zita Man Wai Ng, Karin Kai Wing Wang, Sharen Lee, Haipeng Liu, Ronald Ting Kai Pang, Apichat Kaewdech, Bernard Man Yung Cheung, Gary Tse, Jiandong Zhou

  • August 31, 2026

Related Content

Coding for Ocular Tumors

Ocular tumor coding can be challenging because ocular oncology often involves evolving lesions, diagnostic uncertainty, and terminology that does not always translate cleanly into ICD-10-CM codes. Understanding how to distinguish benign, malignant, in situ, and uncertain histologic behavior neoplasms is essential for accurate coding, medical necessity, and audit defensibility.

Cancer Communication in an Era of Fragmented Trust

Trastuzumab deruxtecan treatment for HER2-low metastatic scrotal extramammary Paget’s disease with bone marrow involvement: a case report